Personalized medicine (PM) aims to provide the best treatment to the right person, with the huge promise to reduce over-medication and to improve compliance, the patient outcomes and the healthcare costs. However, the implementation of PM requires that clinicians use all patient characteristics including lifestyles, genetic, epigenetic, biochemical and molecular profiles during the diagnosis and the follow-up of the patients. Beside PM, the inclusion of patient’s profiles for clinicians, could enable to make an accurate patient stratification, for better predicting disease risk, rating of progression and therapy response.
Once stratified, different sub-groups of patients can be studied for identifying new targets for drug discovery, or the same patient with detailed reports about the disease can be used to identify the best treatment (or set of treatments). To make the best prescription, to find the best drugs and to develop new ones adapted to the heterogeneity of patients across their molecular profiles, computational intelligence algorithms hold the next promise.
This article collection aims to bring together original research articles, data notes and review articles that will present the latest theoretical and technical advancements of Artificial intelligence (AI), machine and deep learning models for drug design and patient stratification.
Other potential topics include (but are not limited to):
- Advanced in intelligent methods for classification and diagnosis of communicable (infection disease) and non-communicable diseases (e.g. Cancer, Metabolic diseases, Neurodegenerative diseases)
- AI and machine learning for imaging (e.g. MRI, EEG, MEG, PET and NIR)
- Data fusion algorithms for scientific data
- Modeling disease models, complexity of multiple
- Fuzzy logic, evolutionary algorithms, and signaling network in diseased organs
Prof. Dr. Serdar Durdagi (SD) has completed his undergraduate and graduate education at Hacettepe University (2001) and Bilkent University (2004), and he was a visiting researcher at the University of Innsbruck in 2005. His doctoral studies were supported by the European Union and his PhD thesis was awarded with the highest degree "summa cum laude" from the Free University of Berlin in 2009. SD conducted his postdoctoral studies at the University of Calgary in the field of computational biophysics. Dr. Durdagi's project applications were also supported by the CIHR and AIHS in 2011. He was a postdoctoral researcher at the Max Planck Institute between 2012 and 2013. In 2014, within the scope of the Marie Curie program SD continued his studies as a faculty member at Bahçeşehir University (BAU). Having around 200 scientific publications in high-impact factor journals, SD's work has been cited more than 4000 times and has an h-index of 39. He has around 20 national and international patents and patent applications. SD's research focuses on the computational and medicinal chemistry applications of biological systems. His group also developing programing codes for several biological problems. (durdagilab.com)
Dr. Ali Farnoud is a senior data engineer/scientist in translational medicine and clinical pharmacology at Boehringer Ingelheim Pharma. He received his PhD from Heidelberg University in 2018. In 2018, he joined Helmholtz Munich as a postdoctoral researcher and worked in Institute of Computational Biology (ICB) and Institute of Lung Biology and Disease (ILBD). Previously, Dr. Farnoud worked as senior development engineer for medical device design and invention at VitroCell GmbH. Currently, he develops and applies machine learning and deep learning methods in translational medicine such as in PK/PD analysis, pharmacogenomics high throughput screens, drug response analysis (inflammatory skin diseases and oncology).
Prof. Amar Abderrahmani(AA) is Full Professor of Cell and Molecular Biology at the Faculty of Medicine at Lille University. He has a multidisciplinary background including a PhD and pharmacy graduation in Molecular genetics and pharmaceutical chemistry. AA has been honored by several Swiss awards and in 2011, of National Chair of Excellence in beta-cell biology, bioscience and diabetes. AA has been member of several scientific committees of Diabetes Association and is currently editor-in-chief of All Life.
Disclosure statement: Dr. Ali Farnoud is an employee at Boehringer Ingelheim Pharma. Prof. Serdar Durdagi and Prof. Amar Abderrahmani have no conflict of interest.
